TECX
What one share of Tectonic Therapeutic holds
Biological Products, (No Diagnostic Substances)
The business and the industry in which Tectonic Therapeutic, Inc. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Tectonic.
Tectonic Therapeutic’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.56 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.85 |
| Cash and investments | $11.80 |
| Book value | $11.64 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$8.34 | $0.17 | −$7.50 | — | −$10.04 |
| 2018 | — | −$3.62 | $0.14 | −$2.94 | — | $5.13 |
| 2019 | — | −$2.66 | $0.06 | −$2.52 | — | $5.88 |
| 2020 | — | −$3.31 | $0.03 | −$2.76 | — | $5.83 |
| 2021 | — | −$2.78 | $0.06 | −$2.34 | — | $3.88 |
| 2022 | — | −$2.42 | $0.01 | −$2.23 | — | −$1.04 |
| 2023 | — | −$33.76 | $0.22 | −$32.29 | — | −$60.12 |
| 2024 | — | −$6.83 | $0.02 | −$6.98 | $0.00 | $9.48 |
| 2025 | — | −$4.05 | $0.01 | −$3.29 | $0.00 | $13.41 |